ArticleJournal of perinatology : official journal of the California Perinatal Association2016
Sildenafil and retinopathy of prematurity risk in very low birth weight infants.
Article in Journal of perinatology : official journal of the California Perinatal Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia (SILDI-SAFE): A Randomized Controlled Trial.The Journal of pediatrics · 2026Trial
- Prophylactic Sildenafil in Preterm Infants at Risk of Bronchopulmonary Dysplasia: A Pilot Randomized, Double-Blinded, Placebo-Controlled Trial.Clinical drug investigation · 2019Trial
- Sildenafil pretreatment attenuates apoptosis and intestinal injury in a hypoxia-ischemia-induced NEC-like rat model.Scientific reports · 2026Article
- Association of Cardiovascular Disease with Retinopathy of Prematurity.Ophthalmic epidemiology · 2023Article
- Early diagnosis and targeted approaches to pulmonary vascular disease in bronchopulmonary dysplasia.Pediatric research · 2022Review
- Update on the use of sildenafil in neonatal pulmonary hypertension: a narrative review of the history, current administration, and future directions.Translational pediatrics · 2021Review
- When to say no to inhaled nitric oxide in neonates?Seminars in fetal & neonatal medicine · 2021Review
- Propranolol for the Treatment of Lymphatic Malformations in a Neonate - A Case Report and Review of Literature.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2020Article
- Sildenafil Exposure in the Neonatal Intensive Care Unit.American journal of perinatology · 2019Article
- Controversies in the identification and management of acute pulmonary hypertension in preterm neonates.Pediatric research · 2017Review
- Diagnostic Approach to Pulmonary Hypertension in Premature Neonates.Children (Basel, Switzerland) · 2017Review
- Sildenafil in Infants and Children.Children (Basel, Switzerland) · 2017Review
- More safety data: what about efficacy of sildenafil?Journal of perinatology : official journal of the California Perinatal Association · 2016Article
- Retinopathy of prematurity: a review of risk factors and their clinical significance.Survey of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 4 countries.
Funding
Abstract
objectiveTo examine the effect of sildenafil therapy on development of severe retinopathy of prematurity (ROP) requiring surgical intervention in premature infants. STUDY
designWe identified premature infants who were discharged from Pediatrix Medical Group neonatal intensive care units from 2003 to 2012 and who received an ophthalmologic exam. We matched each infant exposed to sildenafil before first eye exam to three nonexposed infants using propensity scoring to control for differences in baseline infant characteristics. We evaluated the association between sildenafil exposure and development of severe ROP using conditional logistic regression.
resultOf the 57 815 infants meeting inclusion criteria, 88 were exposed to sildenafil. We matched 81/88 (92%) sildenafil-exposed with 243 nonexposed infants. There was no difference in the proportion of infants who developed severe ROP in the sildenafil-exposed vs nonexposed groups (17/81 (21%) vs 38/243 (16%), P=0.27). On adjusted analysis, there was no difference in severe ROP in the sildenafil-exposed vs nonexposed infants (odds ratio=1.46, 95% confidence interval=0.76 to 2.82, P=0.26).
conclusionWe did not observe an association between risk of severe ROP and sildenafil exposure before first eye exam in this cohort of premature infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.